Magenta Therapeutics Inc (NASDAQ:MGTA) Insider Jason Gardner Sells 14,000 Shares

Magenta Therapeutics Inc (NASDAQ:MGTA) insider Jason Gardner sold 14,000 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $15.11, for a total value of $211,540.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

NASDAQ:MGTA opened at $14.26 on Thursday. The stock has a 50 day moving average price of $15.36. Magenta Therapeutics Inc has a 52 week low of $5.31 and a 52 week high of $21.00. The firm has a market capitalization of $504.46 million and a P/E ratio of -4.56.

Magenta Therapeutics (NASDAQ:MGTA) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.11. On average, analysts expect that Magenta Therapeutics Inc will post -2.03 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Casdin Capital LLC increased its holdings in Magenta Therapeutics by 17.4% in the fourth quarter. Casdin Capital LLC now owns 2,643,317 shares of the company’s stock worth $15,067,000 after buying an additional 392,499 shares during the last quarter. Gilder Gagnon Howe & Co. LLC acquired a new position in Magenta Therapeutics in the first quarter worth approximately $30,127,000. BlackRock Inc. increased its holdings in Magenta Therapeutics by 224.2% in the fourth quarter. BlackRock Inc. now owns 556,381 shares of the company’s stock worth $3,170,000 after buying an additional 384,752 shares during the last quarter. Harvard Management Co. Inc. increased its holdings in Magenta Therapeutics by 23.7% in the fourth quarter. Harvard Management Co. Inc. now owns 411,379 shares of the company’s stock worth $2,345,000 after buying an additional 78,769 shares during the last quarter. Finally, Bessemer Group Inc. acquired a new position in Magenta Therapeutics in the fourth quarter worth approximately $1,352,000. Hedge funds and other institutional investors own 63.62% of the company’s stock.

A number of equities analysts have recently weighed in on MGTA shares. Raymond James started coverage on Magenta Therapeutics in a report on Thursday, March 14th. They issued an “outperform” rating on the stock. Goldman Sachs Group downgraded Magenta Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the company from $17.00 to $16.00 in a report on Sunday, March 24th. They noted that the move was a valuation call. Zacks Investment Research upgraded Magenta Therapeutics from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Saturday, March 23rd. Finally, Wedbush restated an “outperform” rating and issued a $22.00 price objective on shares of Magenta Therapeutics in a report on Friday, May 10th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $19.00.

Magenta Therapeutics Company Profile

Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.

See Also: What does cost of debt say about a company’s financial health?

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.